Abstract: A compound of formula ##STR1## in which A represents S;R.sub.1 is selected from the group consisting of OH, (C.sub.1 -C.sub.12)alkyl, (C.sub.1 -C.sub.12)alkoxy, benzyloxy, phenyl, benzyl (C.sub.1 -C.sub.4)alkyl NZ.sub.1 Z.sub.2, and NZ.sub.1 Z.sub.2 ;R.sub.2 is selected from the group consisting of OH, SH, (C.sub.1 -C.sub.4)alkoxy, (C.sub.1 -C.sub.4)alkylthio, and NZ.sub.1 Z.sub.2 ;R.sub.3 is selected from the group consisting of H, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkylthio, (C.sub.1 -C.sub.4)alkoxy, phenyl, and benzyl;B is selected from the group consisting of phenyl; pyridyl; phenyl substituted by one or more groups selected from halo, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, CF.sub.3, CH.sub.2 NZ.sub.1 Z.sub.2, and NZ.sub.1 Z.sub.2 wherein Z.sub.1 and Z.sub.2 are selected, independently of each other, from the group consisting of H, (C.sub.1 -C.sub.6)alkyl, formyl, and benzyl or --NZ.sub.1 Z.sub.

Abstract: Compounds of formula ##STR1## in which R.sub.1 represents OH, (C.sub.1 -C.sub.12)alkyl, (C.sub.1 -C.sub.12)alkoxy, benzyloxy, benzyl, phenyl, (C.sub.1 -C.sub.4)alkylNZ.sub.1 Z.sub.2 or NZ.sub.1 Z.sub.2 ; R.sub.2 represents OH, SH, (C.sub.1 -C.sub.4)alkoxy, (C.sub.1 -C.sub.4)alkylthio or NZ.sub.1 Z.sub.2 ; R.sub.3 represents H, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkylthio, (C.sub.1 -C.sub.4)alkoxy, phenyl or benzyl; A represents N and R represents H or (C.sub.1 -C.sub.4)alkyl which can be substituted by phenyl or NZ.sub.1 Z.sub.2 ; B represents phenyl which is coupled to the pyridyl ring and is optionally substituted by one or more groups chosen from halo, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, CF.sub.3, CH.sub.2 NZ.sub.1 Z.sub.2 or NZ.sub.1 Z.sub.2 ; and Z.sub.1 and Z.sub.2 represent, independently of each other, H, (C.sub.1 -C.sub.6) alkyl, formyl or benzyl, or they form with the nitrogen atom to which they are attached an optionally substituted saturated heterocycle and their salts.

Abstract: The invention concerns a method of treatment and prophylaxis of depression and stress by means of a phenylethanolaminotetralin of formula (I) ##STR1## wherein A is a (C.sub.1 -C.sub.4)alkylene radical and R represents a hydrogen atom or a (C.sub.1 -C.sub.4)alkyl group, or a pharmaceutically acceptable salts thereof.

Abstract: A method of treatment of anxiety and depression in mammals is described which comprises administering to a mammal in need thereof an effective amount of a trifluoromethylphenyl-tetrahydropyridine derivative of formula I ##STR1## wherein Alk represents a straight or branched (C.sub.1 -C.sub.4)alkylene chain and R is selected from the group consisting of cyano, acetyl, (C.sub.3 -C.sub.7)cycloalkyl, pyridyl, 1-oxide-pyridyl and naphthyl, or of a pharmaceutically acceptable salt thereof.

Abstract: The present invention concerns new derivatives of 4-oxo-1,4-dihydro-quinoline 3-carboxamide, answering to the following general formula: ##STR1## in which: R.sub.1 represents a linear or branched lower alkyl radical, containing from 1 to 5 carbon atoms; an alkenyl or alkynyl radical containing from 2 to 5 carbon atoms; or a cycloalkyl radical containing from 3 to 5 carbon atoms,R.sub.2 represents an alkyl radical containing from 1 to 4 carbon atoms, n is equal to 1 or 2,X represents a hydrogen, a halogen, a lower alkoxy or alkyl group.The invention also concerns their application as medicaments and the compositions containing them.

Abstract: The present invention relates to new quinolylglycinamide derivatives corresponding to the following general formula: ##STR1## The invention also relates to a process for preparing these compounds and their therapeutic application as a psychotropic agent.

Abstract: The chemical compounds of the invention are useful as the active compound in drugs because of their anticonvulsant and/or antianoxic activity. They have the general formula ##STR1## wherein Z is a hydroxyl group; a group--OM wherein M is an alkali metal atom or an equivalent atom fraction of an alkaline-earth metal or an amino group such as --NH.sub.2, and R is a linear or branched alkyl group containing from 1 to 9 carbon atoms, and optionally substituted by one or more halogen atoms; a linear or branched alkenyl or alkynyl, alkoxyalkyl, or acylalkyl group containing from 2 to 9 carbon atoms and optionally substituted by one or more halogen atoms; an aryl or arylalkyl or aryloxyalkyl group comprising at least one aromatic radical and an alkyl chain having from 1 to 4 carbon atoms.

Abstract: Prostaglandin derivatives corresponding to the general formula: ##STR1## wherein R.sub.1 represents hydrogen, methyl or ethyl, R.sub.2, R.sub.3 and R.sub.4, which are the same or different, each represent hydrogen or methyl and R is selected from the groups consisting of: ##STR2## in which R.sub.5 represents hydrogen, methyl or ethyl, R.sub.6 represents methyl, ethyl or acetyl and R.sub.7 and R.sub.8, when they are different, each represent hydrogen or a branched- or straight-chain alkyl group having from 1 to 7 carbon atoms or R.sub.7 and R.sub.8, when they are identical, each represent hydrogen or a straight-chain alkyl group having from 1 to 3 carbon atoms with the provisos that:When both R.sub.7 and R.sub.8 represent hydrogen, R.sub.5 is methyl or ethyl,When R.sub.5 represents methyl and R.sub.2, R.sub.3, R.sub.4, R.sub.7 and R.sub.8 all represent hydrogen then R.sub.1 is ethyl,The said prostaglandin derivatives being in the form of a mixture of isomers or of an individual isomer.